Processa Pharmaceuticals Stock Forecast, Price & News

-0.17 (-2.49 %)
(As of 06/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume61,445 shs
Average Volume65,833 shs
Market Capitalization$103.22 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PCSA News and Ratings via Email

Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Processa Pharmaceuticals logo

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.17 out of 5 stars

Medical Sector

1009th out of 2,100 stocks

Pharmaceutical Preparations Industry

492nd out of 832 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Processa Pharmaceuticals (NASDAQ:PCSA) Frequently Asked Questions

Is Processa Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Processa Pharmaceuticals stock.
View analyst ratings for Processa Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Processa Pharmaceuticals?

Wall Street analysts have given Processa Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Processa Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Processa Pharmaceuticals' next earnings date?

Processa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Processa Pharmaceuticals

How were Processa Pharmaceuticals' earnings last quarter?

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) posted its quarterly earnings results on Thursday, May, 13th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.03.
View Processa Pharmaceuticals' earnings history

How has Processa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Processa Pharmaceuticals' stock was trading at $9.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PCSA stock has decreased by 31.8% and is now trading at $6.65.
View which stocks have been most impacted by COVID-19

Who are Processa Pharmaceuticals' key executives?

Processa Pharmaceuticals' management team includes the following people:
  • Dr. David Young, Co-Founder, Chairman, Pres & CEO (Age 68, Pay $58.33k)
  • Mr. Patrick Lin, Co-Founder, Chief Bus. & Strategy Officer (Age 56, Pay $96.18k)
  • Dr. Sian E. Bigora Ph.D., Pharm.D., Co-Founder & Chief Devel. Officer (Age 61, Pay $100.46k)
  • Ms. Wendy J. Guy, Co-Founder & Chief Admin. Officer (Age 57, Pay $88.41k)
  • Mr. James H. Stanker, Chief Financial Officer (Age 63, Pay $87.5k)
  • Mr. Robert Michael Floyd, Chief Operating Officer (Age 65, Pay $98.98k)

Who are some of Processa Pharmaceuticals' key competitors?

What is Processa Pharmaceuticals' stock symbol?

Processa Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCSA."

Who are Processa Pharmaceuticals' major shareholders?

Processa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.61%), Worth Venture Partners LLC (0.59%), Essex Investment Management Co. LLC (0.47%), Janney Montgomery Scott LLC (0.41%), Geode Capital Management LLC (0.18%) and Coastal Bridge Advisors LLC (0.13%). Company insiders that own Processa Pharmaceuticals stock include James E Besser and Justin W Yorke.
View institutional ownership trends for Processa Pharmaceuticals

Which major investors are selling Processa Pharmaceuticals stock?

PCSA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Janney Montgomery Scott LLC, and Essex Investment Management Co. LLC. Company insiders that have sold Processa Pharmaceuticals company stock in the last year include James E Besser, and Justin W Yorke.
View insider buying and selling activity for Processa Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Processa Pharmaceuticals stock?

PCSA stock was bought by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC, Geode Capital Management LLC, Coastal Bridge Advisors LLC, Citadel Advisors LLC, Citadel Advisors LLC, Northern Trust Corp, and Commonwealth Equity Services LLC.
View insider buying and selling activity for Processa Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Processa Pharmaceuticals?

Shares of PCSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Processa Pharmaceuticals' stock price today?

One share of PCSA stock can currently be purchased for approximately $6.65.

How much money does Processa Pharmaceuticals make?

Processa Pharmaceuticals has a market capitalization of $103.22 million.

How many employees does Processa Pharmaceuticals have?

Processa Pharmaceuticals employs 14 workers across the globe.

What is Processa Pharmaceuticals' official website?

The official website for Processa Pharmaceuticals is

Where are Processa Pharmaceuticals' headquarters?

Processa Pharmaceuticals is headquartered at 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076.

How can I contact Processa Pharmaceuticals?

Processa Pharmaceuticals' mailing address is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. The company can be reached via phone at 443 776 3133 or via email at [email protected]

This page was last updated on 6/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.